Showing 1 – 3 of 3
Relevance | Newest | Oldest |
  • JAMA Original Investigation
    April 6, 2024

    Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial

    Richard M.听Martin,聽BM, BS, PhD; Emma L.听Turner,聽PhD; Grace J.听Young,聽MSc; Chris聽Metcalfe,聽PhD; Eleanor I.听Walsh,聽MSc; J. Athene聽Lane,聽PhD; Jonathan A. C.听Sterne,聽PhD; Sian聽Noble,聽PhD; Peter聽Holding,聽MSc; Yoav聽Ben-Shlomo,聽MBBS, PhD; Naomi J.听Williams,聽PhD; Nora聽Pashayan,聽MD, PhD; Mai Ngoc聽Bui,聽PhD; Peter C.听Albertsen,聽MD; Tyler M.听Seibert,聽MD, PhD; Anthony L.听Zietman,聽MD; Jon聽Oxley,聽MD; Jan聽Adolfsson,聽MD; Malcolm D.听Mason,聽MD; George聽Davey Smith,聽DSc; David E.听Neal,聽MD; Freddie C.听Hamdy,聽MD; Jenny L.听Donovan,聽PhD; CAP Trial Group
    Abstract Full Text
    is active quiz has multimedia
    JAMA. 2024; 331(17):1460-1470. 10.1001/jama.2024.4011

    This secondary analysis of a randomized clinical trial assesses whether screening for prostate-specific antigen reduces prostate cancer mortality at 15-year follow-up.

  • JAMA Oncology Original Investigation
    February 18, 2021

    Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial

    Adnan聽Ali,聽MBBS; Alex聽Hoyle,聽MBBS, MRCS, MD; 脕ine M.听Haran,聽MRCS; Christopher D.听Brawley,聽MSc; Adrian聽Cook,聽MSc; Claire聽Amos,聽PhD; Joanna聽Calvert,聽MSc; Hassan聽Douis,聽PhD; Malcolm D.听Mason,聽MD; David聽Dearnaley,聽MA, MD; Gerhardt聽Attard,聽MD, PhD; Silke聽Gillessen,聽MD; Mahesh K. B.听Parmar,聽DPhil; Christopher C.听Parker,聽MD; Matthew R.听Sydes,聽MSc; Nicholas D.听James,聽MBBS, PhD; Noel W.听Clarke,聽MBBS, ChM
    Abstract Full Text
    open access
    JAMA Oncol. 2021; 7(4):555-563. 10.1001/jamaoncol.2020.7857

    This exploratory analysis of a randomized clinical trial evaluates the association of bone metastasis count and location with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer.

  • JAMA Oncology Original Investigation
    March 1, 2016

    Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial

    Nicholas D.听James,聽BSc, MBBS, PhD, FRCP, FRCR; Melissa R.听Spears,聽MSc, BSc; Noel W.听Clarke,聽MBBS, FRCS(Eng), ChM(Manch), FRCS(Urol); David P.听Dearnaley,聽MA, MB, BChir, MD, FRCP, FRC; Malcolm D.听Mason,聽MD, FRCP, FRCR, FSB; Christopher C.听Parker,聽BA, BM, BChir, MD; Alastair W. S.听Ritchie,聽MD, FRCSEd; J. Martin聽Russell,聽BSc, MB, ChB, MRCP(UK), FRCR, FRCPSG; Francesca聽Schiavone,聽PhD; Gerhardt聽Attard,聽MD, PhD; Johann S.听de Bono,聽MBChB, MSc, PhD, FRCP, FMedSci; Alison聽Birtle,聽MB, BS, MRCP, FRCR, MD; Daniel S.听Engeler,聽MD; Tony聽Elliott,聽BSc, MSc, PhD, MBChB, MRCP, FRCR; David聽Matheson,聽BSc, PGCE, DipEd, MEd, PhD, FRSA, FHEA; Joe聽O鈥橲ullivan,聽MD, FRCR, FFRRCSI, FRCPI; Delia聽Pudney,聽MBChB; Narayanan聽Srihari,聽MB, BS; Jan聽Wallace,聽MB, ChB, FRCR; Jim聽Barber,聽MA, DM, FRCR, MRCP; Isabel聽Syndikus,聽MD; Mahesh K. B.听Parmar,聽DPhil, MSc, BSc; Matthew R.听Sydes,聽MSc, CStat; for the STAMPEDE Investigators
    Abstract Full Text
    open access
    JAMA Oncol. 2016; 2(3):348-357. 10.1001/jamaoncol.2015.4350

    This study of patients allocated to the control arm of the STAMPEDE Trial explored the survival and the effect on survival of radiotherapy by nodal involvement in high-risk, hormone-naive men with newly diagnosed nonmetastatic prostate cancer starting long-term hormone therapy for the first time.